Use avidity to identify the best NK cell with optimal response

Part of: CAR-NK / NK cells

Use avidity to identify the best NK cell with optimal response

In addition to autologous cellular therapy, allogeneic strategies may facilitate an off-the-shelf solution, including NK cells as a prime example.

In this assay, researchers from Glycostem Therapeutics B.V. compared cell avidity data with cell killing by evaluating NK functionalities from two different donors (donor 1 and donor 2).

NK cells from donor 2 induced 3-fold higher cytotoxicity compared with  NK cells from donor 1 (74% and 24%, respectively). NK cells from donor 2 required higher forces than those from donor 1 to detach from target cells (Figure 1).

The data suggest that cell avidity is a reliable predictor of NK cell function and that cell avidity analyses can be applied to different types of immune cells.

1 Left: Cytotoxic effect of NK cells from donor 1 and donor 2 on the same population of target cells. Right: Avidity curve showing the proportion of target-bound NK cells upon application of a force ramp. (rForce indicates relative force).

Data courtesy of Glycosystem Therapeutics B.V.


z-Movi® High-throughput Label-free Cell Interaction Studies

The z-Movi® is a unique instrument that measures the avidity between immune cells and their targets, enabling you to identify the most potent immunotherapeutic effector cells. This new technology provides you with predictive, reproducible, and fast high-throughput results at a single-cell resolution without compromising cell viability. All within a compact little box that easily fits inside the flow hood for sterile and safe sample handling

    Download the brochure to learn more

    Would you like to receive exclusive news on the latest publications, events, and breakthrough science from the dynamic single-molecule and cell avidity analysis communities?
    Yes, pleaseNo, thank you

    You can unsubscribe at any time from our marketing emails. By submitting the form you agree to LUMICKS' privacy policy.

    Join our newsletter

    Join our newsletter

    Get exclusive news on the latest publications, product developments, events and breakthrough science.

    By agreeing to receive marketing communications, you subscribe to our newsletter. You can change your mind at any time by clicking the unsubscribe link in any marketing email you receive from us. By submitting the form you agree to LUMICKS' privacy policy.

    Download our webinar recording:


    Download our Cell Therapy (CAR-T, TCR, NK) applications deck